{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:07:48Z","timestamp":1780700868228,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Deputyship for research and innovation, Ministry of Education in Saudi Arabia","award":["IFP22UQU4320605DSR178"],"award-info":[{"award-number":["IFP22UQU4320605DSR178"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00228-023-03508-1","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:03:10Z","timestamp":1684396990000},"page":"961-966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies"],"prefix":"10.1007","volume":"79","author":[{"given":"Ahmed","family":"Elkeraie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Zyada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud E.","family":"Elrggal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elrggal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"issue":"15","key":"3508_CR1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"22","key":"3508_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128","journal-title":"N Engl J Med"},{"issue":"4","key":"3508_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334","journal-title":"N Engl J Med"},{"issue":"7","key":"3508_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"16","key":"3508_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"4","key":"3508_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"24","key":"3508_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"7","key":"3508_CR8","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI (2022) Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep 7(7):1463\u20131476","journal-title":"Kidney Int Rep"},{"issue":"7","key":"3508_CR9","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.34067\/KID.0000732021","volume":"2","author":"N Patel","year":"2021","unstructured":"Patel N, Hindi J, Farouk SS (2021) Sodium-glucose cotransporter 2 inhibitors and kidney transplantation: what are we waiting for? Kidney 2(7):1174\u20131178","journal-title":"Kidney"},{"issue":"9","key":"3508_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W et al (2018) Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6(9):691\u2013704","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3508_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajem.2021.02.015","volume":"44","author":"B Long","year":"2021","unstructured":"Long B, Lentz S, Koyfman A, Gottlieb M (2021) Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med 44:157\u2013160","journal-title":"Am J Emerg Med"},{"key":"3508_CR12","unstructured":"KDIGO Announces Launch of CKD Guideline Update \u2013 KDIGO [Internet]. [cited 2023 Mar 21]. Available from: https:\/\/kdigo.org\/kdigo-announces-launch-of-ckd-guidelineupdate\/"},{"issue":"9","key":"3508_CR13","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","volume":"37","author":"DC Wheeler","year":"2022","unstructured":"Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF et al (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant 37(9):1647\u20131656","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3508_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T et al (2021) A prespecified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215\u2013224","journal-title":"Kidney Int"},{"issue":"7","key":"3508_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","volume":"37","author":"EMPA-KIDNEY Collaborative Group","year":"2022","unstructured":"EMPA-KIDNEY Collaborative Group (2022) Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 37(7):1317\u20131329","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"3508_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"Empagliflozin in patients with chronic kidney disease","year":"2023","unstructured":"Empagliflozin in patients with chronic kidney disease (2023) N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"},{"issue":"7","key":"3508_CR17","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.2337\/dc17-0237","volume":"40","author":"H Rajasekeran","year":"2017","unstructured":"Rajasekeran H, Kim SJ, Cardella CJ, Schiff J, Cattral M, Cherney DZI et al (2017) Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series. Diabetes Care 40(7):e75\u2013e76","journal-title":"Diabetes Care"},{"issue":"6","key":"3508_CR18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","volume":"42","author":"TAS Halden","year":"2019","unstructured":"Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J et al (2019) Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42(6):1067\u20131074","journal-title":"Diabetes Care"},{"issue":"3","key":"3508_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/ajt.15223","volume":"19","author":"E Schwaiger","year":"2019","unstructured":"Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A et al (2019) Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 19(3):907\u2013919","journal-title":"Am J Transplant"},{"issue":"10","key":"3508_CR20","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","volume":"51","author":"N Attallah","year":"2019","unstructured":"Attallah N, Yassine L (2019) Use of empagliflozin in recipients of kidney transplant: a report of 8 cases. Transplant Proc 51(10):3275\u20133280","journal-title":"Transplant Proc"},{"issue":"5","key":"3508_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1159\/000501854","volume":"44","author":"M Mahling","year":"2019","unstructured":"Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M (2019) Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 44(5):984\u2013992","journal-title":"Kidney Blood Press Res"},{"issue":"9","key":"3508_CR22","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","volume":"106","author":"J-H Lim","year":"2022","unstructured":"Lim J-H, Kwon S, Jeon Y, Kim YH, Kwon H, Kim YS et al (2022) The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation 106(9):e404\u2013e412","journal-title":"Transplantation"},{"key":"3508_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03539-8","author":"H Hammad","year":"2023","unstructured":"Hammad H, Shaaban A, Philips MV, Fayed A, Abdelaziz TS (2023) Effect of sodium-glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-023-03539-8","journal-title":"Int Urol Nephrol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03508-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T07:01:44Z","timestamp":1686985304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03508-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3508"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03508-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the KUC local ethical committee (number: KUC-I-1-1020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}